Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial.
Stockem CF, Mellema JJJ, van Rhijn BWG, Boellaard TN, van Montfoort ML, Balduzzi S, Boormans JL, Franckena M, Meijer RP, Robbrecht DGJ, Suelmann BBM, Schaake EE, van der Heijden MS. Stockem CF, et al. Among authors: schaake ee. Front Oncol. 2023 Aug 29;13:1246603. doi: 10.3389/fonc.2023.1246603. eCollection 2023. Front Oncol. 2023. PMID: 37711193 Free PMC article.
Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: A convenient alternative to 5-fluorouracil.
Voskuilen CS, van de Kamp MW, Schuring N, Mertens LS, Noordzij A, Pos F, van Rhijn BWG, van der Heijden MS, Schaake EE. Voskuilen CS, et al. Among authors: schaake ee. Radiother Oncol. 2020 Sep;150:275-280. doi: 10.1016/j.radonc.2020.07.057. Epub 2020 Aug 6. Radiother Oncol. 2020. PMID: 32768507
A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice.
de Ruiter BM, van de Kamp MW, van Steenbergen JPZ, Franckena M, Boormans JL, de Feijter JM, Bins AD, Hulshof MCCM, de Reijke TM, Schaake E, Oddens JR. de Ruiter BM, et al. Eur Urol Open Sci. 2022 Mar 16;39:7-13. doi: 10.1016/j.euros.2022.02.010. eCollection 2022 May. Eur Urol Open Sci. 2022. PMID: 35528785 Free PMC article.
Survival after neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer.
Einerhand SMH, van Dijk N, van Dorp J, de Feijter JM, van Montfoort ML, van de Kamp MW, Schaake EE, Boellaard TN, Hendricksen K, van der Heijden MS, van Rhijn BWG. Einerhand SMH, et al. Among authors: schaake ee. Int J Cancer. 2022 Dec 1;151(11):2004-2011. doi: 10.1002/ijc.34125. Epub 2022 Jun 10. Int J Cancer. 2022. PMID: 35603905 Clinical Trial.
Patterns of Recurrence and Survival After Pelvic Treatment for Locally Advanced Penile Cancer.
de Vries HM, Ottenhof SR, Rafael TS, van Werkhoven E, Pos FJ, van Rhijn BWG, Moonen LMF, Graafland N, de Feijter JM, Schaake EE, Horenblas S, Brouwer OR. de Vries HM, et al. Among authors: schaake ee. Eur Urol Open Sci. 2022 Dec 15;47:29-35. doi: 10.1016/j.euros.2022.11.005. eCollection 2023 Jan. Eur Urol Open Sci. 2022. PMID: 36601037 Free PMC article.
A Prospective Study of Chemoradiotherapy as Primary Treatment in Patients With Locoregionally Advanced Penile Carcinoma.
Ottenhof SR, de Vries HM, Doodeman B, Vrijenhoek GL, van der Noort V, Donswijk ML, de Feijter JM, Schaake EE, Horenblas S, Brouwer OR, van der Heijden MS, Pos FJ. Ottenhof SR, et al. Among authors: schaake ee. Int J Radiat Oncol Biol Phys. 2023 Sep 1;117(1):139-147. doi: 10.1016/j.ijrobp.2023.03.066. Epub 2023 Apr 6. Int J Radiat Oncol Biol Phys. 2023. PMID: 37030606
Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II Trial.
de Vries HM, Rafael TS, Gil-Jimenez A, de Feijter JM, Bekers E, van der Laan E, Lopez-Yurda M, Hooijberg E, Broeks A, Peters D, Seignette IM, Pos FJ, Horenblas S, van Rhijn BWG, Jordanova ES, Brouwer OR, Schaake E, van der Heijden MS. de Vries HM, et al. J Clin Oncol. 2023 Nov 1;41(31):4872-4880. doi: 10.1200/JCO.22.02894. Epub 2023 Jul 24. J Clin Oncol. 2023. PMID: 37487169 Clinical Trial.
Reply to Y.-N. Feng et al.
de Vries HM, Brouwer OR, Schaake E, van der Heijden MS. de Vries HM, et al. J Clin Oncol. 2024 Jan 10;42(2):243-244. doi: 10.1200/JCO.23.02069. Epub 2023 Nov 16. J Clin Oncol. 2024. PMID: 37972345 No abstract available.
Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making.
Post CCB, Mens JWM, Haverkort MAD, Koppe F, Jürgenliemk-Schulz IM, Snyers A, Roeloffzen EMA, Schaake EE, Slot A, Stam TC, Beukema JC, van den Berg HA, Lutgens LCHW, Nijman HW, de Kroon CD, Kroep JR, Stiggelbout AM, Creutzberg CL. Post CCB, et al. Among authors: schaake ee. Gynecol Oncol. 2021 Jun;161(3):727-733. doi: 10.1016/j.ygyno.2021.03.004. Epub 2021 Mar 10. Gynecol Oncol. 2021. PMID: 33712276 Free article.
40 results